Use of NSAIDs, smoking and lung cancer risk

Abstract

We investigated the risk of lung cancer in relation to non-steroidal anti-inflammatory drugs (NSAIDs) among 573 cases and 857 sex-and age-matched controls for whom we had information on use of NSAIDs, from a prescription database covering all pharmacies in Denmark since 1995, and self-reported NSAID use, smoking habits and other potential confounders. Associations were expressed as odds ratios, assessed by logistic regression in unmatched analyses. After controlling for smoking habits, length of education and concomitant use of acetaminophen, we found a slightly decreased relative risk of 0.86 (95% confidence intervals, 0.65 -1.14) for lung cancer associated with any use of NSAIDs. The risk decreased significantly (P ¼ 0.02) with increasing numbers of dispensed prescriptions per year during the 1 -3 years before the index date with a relative risk of 0.49 (0.28 -0.84) among those with four or more prescriptions per year during this period. Our findings suggest that regular use of NSAIDs is associated with a slightly or moderately reduced risk for lung cancer.

Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study

“…The self-reported information on NSAID use at study baseline enabled us to evaluate drug exposure prior to the study period; however, we had no information on duration of use before enrollment. A comparison of selfreported use and prescription records revealed that of individuals filling two or more prescriptions for aspirin within one year prior to enrollment, 98% reported aspirin use at enrollment, indicating good reliability of the questionnaire to capture aspirin use [56]. Although we adjusted for a wide range of established CRC risk factors, we cannot rule out confounding by unmeasured factors associated with both NSAID use and CRC risk.…”

Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention

“…20 The use of NSAIDs was also linked to the protective effects against cancers in other sites such as breast, esophagus, stomach, lung, prostate and ovary. [21][22][23][24][25][26][27][28][29] However, the results for these cancer types are less consistent compared to those for colorectal cancer.…”

Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer

“…However, reported results of aspirin use and lung cancer risk are conflicting, with both protective [13][14][15][16][17][18][19][20][21] and null effects [22][23][24][25][26][27][28][29][30][31][32] being reported. Three clinical trials focusing on chemoprevention with aspirin reported non-significant protective effects [35][36][37], and a recent pooled analysis of individual-level data from 7 clinical trials of daily aspirin reported a protective effect on lung cancer death, with a protective latent period of about 5 years.…”